Aquestive Therapeutics (AQST) Accounts Payables (2017 - 2025)
Historic Accounts Payables for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $10.9 million.
- Aquestive Therapeutics' Accounts Payables rose 4348.92% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 4348.92%. This contributed to the annual value of $10.3 million for FY2024, which is 1524.76% up from last year.
- Latest data reveals that Aquestive Therapeutics reported Accounts Payables of $10.9 million as of Q3 2025, which was up 4348.92% from $12.0 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Accounts Payables peaked at $12.4 million during Q1 2023, and registered a low of $5.7 million during Q2 2024.
- In the last 5 years, Aquestive Therapeutics' Accounts Payables had a median value of $9.9 million in 2022 and averaged $9.4 million.
- In the last 5 years, Aquestive Therapeutics' Accounts Payables plummeted by 5921.11% in 2021 and then soared by 10981.39% in 2025.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Accounts Payables stood at $8.3 million in 2021, then rose by 19.63% to $9.9 million in 2022, then fell by 10.26% to $8.9 million in 2023, then grew by 15.25% to $10.3 million in 2024, then increased by 5.62% to $10.9 million in 2025.
- Its Accounts Payables stands at $10.9 million for Q3 2025, versus $12.0 million for Q2 2025 and $12.3 million for Q1 2025.